Please login to the form below
Inclisiran
This page shows the latest Inclisiran news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Leqvio shows sustained efficacy and safety for cardiac patients
Low-density lipoprotein cholesterol level reduction was sustained over four years. Novartis has announced new long-term Leqvio (inclisiran) data, showing sustained efficacy and safety over a four-year period in
Latest news
-
Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
Also, Novartis’ Leqvio (inclisiran) – which has the added convenience of only being injected once every six months – has been approved in Europe but has only just started to be rolled out.
-
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
Inclisiran represents a potential game-changer in preventing thousands of people from dying prematurely from heart attacks and strokes,” said NICE deputy chief executive, Meindert Boysen. ... Inclisiran is particularly attractive because it only needs
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
mark. The company also said it had resubmitted its cholesterol-lowering med inclisiran in the US, after the Food and Drug Administration (FDA) issued a Complete Response Letter earlier this year ... In the EU, inclisiran is already approved under the
-
Novartis announces delay in UK cholesterol drug study
Leqvio (inclisiran) is a small interfering RNA (sIRNA) with a new mechanism of action that allows it to deliver effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients
-
Novartis scores CHMP backing for cholesterol drug Leqvio
Leqvio ( inclisiran) is a potential first-in-class treatment for high cholesterol in Europe for patients with hypercholesterolemia or mixed dyslipidemia.
More from news
Approximately 10 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Are smart deals a clever solution to UK market access?
Perhaps the most widely known of these was the deal struck with Novartis for access to its novel cholesterol drug, Leqvio (inclisiran).
-
Cortellis Drugs to Watch in 2020 report
8. Inclisiran from The Medicines Company (now a Novartis wholly owned subsidiary) is being reviewed for approval in hypercholesterolemia in the US and the EU. ... Inclisiran must leverage its strong efficacy and twice-a-year dosing to succeed.
-
20 for 2020 – Five pharma leaders to watch in 2020
Meanwhile, there’s considerable excitement about Novartis-partnered cholesterol-lowering therapy inclisiran, which is also up for an FDA decision this year and has been tipped to become a mega-blockbuster
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for hypercholesterolemia being co-developed by the Medicines Company; and lumisiran
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
- Why everyone in pharma is bending over backwards to be agile
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
